Eculizumab Shows Promise in Treating Severe HELLP Syndrome With Thrombotic Microangiopathy
A 41-year-old patient with severe HELLP syndrome and thrombotic microangiopathy experienced rapid clinical recovery following targeted anti-complement therapy.










